HEART-STRONG: SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction

Assessing a once-daily SGLT2 inhibitor for reducing cardiovascular death and heart failure hospitalizations in adults with symptomatic HFpEF.

Key eligibility criteria

• Adults ≥ 40 years
• NYHA class II–IV symptoms
• LVEF > 40%
• Elevated NT-proBNP

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.